Last reviewed · How we verify
DTaP-IPV-HB-Hib vaccine — Competitive Intelligence Brief
phase 3
vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
DTaP-IPV-HB-Hib vaccine (DTaP-IPV-HB-Hib vaccine) — Sanofi Pasteur, a Sanofi Company. This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DTaP-IPV-HB-Hib vaccine TARGET | DTaP-IPV-HB-Hib vaccine | Sanofi Pasteur, a Sanofi Company | phase 3 | vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Fluarix Tetra Vaccine | Fluarix Tetra Vaccine | GlaxoSmithKline | marketed | Inactivated influenza vaccine | ||
| Inactivated SARS-CoV-2 Vaccine (Vero cell) | Inactivated SARS-CoV-2 Vaccine (Vero cell) | Sinovac Research and Development Co., Ltd. | marketed | inactivated viral vaccine | SARS-CoV-2 spike protein and other viral antigens | |
| AVA | AVA | Emergent BioSolutions | marketed | Inactivated bacterial vaccine | Bacillus anthracis protective antigen (PA) and lethal factor | |
| Live Attenuated H1N1 Influenza Vaccine | Live Attenuated H1N1 Influenza Vaccine | University of Rochester | marketed | Live attenuated vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (vaccine class)
- Pfizer · 20 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
- GlaxoSmithKline · 12 drugs in this class
- Merck Sharp & Dohme LLC · 12 drugs in this class
- Centers for Disease Control and Prevention · 9 drugs in this class
- Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
- Beijing Center for Disease Control and Prevention · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
- Sinovac Biotech Co., Ltd · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DTaP-IPV-HB-Hib vaccine CI watch — RSS
- DTaP-IPV-HB-Hib vaccine CI watch — Atom
- DTaP-IPV-HB-Hib vaccine CI watch — JSON
- DTaP-IPV-HB-Hib vaccine alone — RSS
- Whole vaccine class — RSS
Cite this brief
Drug Landscape (2026). DTaP-IPV-HB-Hib vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-ipv-hb-hib-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab